Back to Search
Start Over
Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia.
- Source :
- Leukemia & Lymphoma; Dec2011, Vol. 52 Issue 12, p2321-2328, 8p, 1 Diagram, 3 Charts, 2 Graphs
- Publication Year :
- 2011
-
Abstract
- This study analyzed the results of stem cell transplant (SCT) in elderly patients with acute myeloid leukemia (AML) who achieved complete remission (CR) with a gemtuzumab ozogamicin (GO)-containing regimen in order to identify the impact of the drug as a remission induction regimen on the outcome of SCT. Patients who achieved CR with GO proceeded to reduced-intensity conditioning or autologous SCT after one or two cycles of consolidation chemotherapy. With a median follow-up of 53.5 months ( n - 17), probabilities of overall survival (OS) and disease-free survival (DFS) at 3 years were 58.2 ± 12.1% and 47.1 ± 12.1%, respectively, and the cumulative incidences of relapse and non-relapse mortality were 35.3 ± 12.1%, and 17.7 ± 9.5%, respectively. Patients with high bone marrow CD33 expression at the time of diagnosis showed significantly higher OS and DFS (70.7%, p == 0.008 and 57.1%, p == 0.008, respectively) than those with low expression. The intensification of post-remission treatment using SCT in elderly patients with AML who achieve CR on GO appears to be an effective and feasible treatment modality. [ABSTRACT FROM AUTHOR]
- Subjects :
- STEM cell transplantation
MYELOID leukemia
BONE marrow
DRUG therapy
IMMUNE system
Subjects
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 52
- Issue :
- 12
- Database :
- Complementary Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 67463001
- Full Text :
- https://doi.org/10.3109/10428194.2011.587562